Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 17Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Colonic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Thyroid Neoplasms 7Pancreatic Neoplasms 7Cholangiocarcinoma 7Breast Neoplasms 7Esophageal Neoplasms 6Sarcoma 5Neuroendocrine Tumors 5Lung Neoplasms 5Head and Neck Neoplasms 5Gastrointestinal Neoplasms 5Biliary Tract Neoplasms 5Adenocarcinoma 5Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neoplasms by Site 4Lung Diseases 4Liver Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Triple Negative Breast Neoplasms × Gastrointestinal × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡